The Indian government has banned the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs, including those containing paracetamol, citing public health concerns. The ban was announced on June 20, 2026, with authorities highlighting the lack of therapeutic justification and potential risks to human health, according to livemint.com.
The decision follows a review by the Union health ministry, which found that these FDCs did not meet the required standards for safety and efficacy. The banned drugs include combinations such as Nimesulide with paracetamol, which were deemed to pose unnecessary health risks. The government has prohibited all activities related to these drugs to protect public health, as detailed by livemint.com.
Fixed-dose combination drugs have been under scrutiny in India due to concerns about irrational formulations that can lead to adverse effects and antibiotic resistance. This ban aligns with previous regulatory efforts to ensure drug safety and rational use. The move is part of broader measures to regulate pharmaceutical products and safeguard consumers, as reported by livemint.com.
The ban on these 16 FDC drugs takes effect immediately, with the government enforcing strict compliance across the pharmaceutical industry. Manufacturers and sellers have been directed to cease operations involving these combinations, reinforcing regulatory oversight in drug safety, according to livemint.com.